Pooled analysis of the reports of carfilzomib, panobinostat, and elotuzumab combinations in patients with refractory/relapsed multiple myeloma.

about

Carfilzomib boosted combination therapy for relapsed multiple myeloma The cyclin-dependent kinase 4/6 inhibitor, abemaciclib, exerts dose-dependent cytostatic and cytocidal effects and induces autophagy in multiple myeloma cells.

P2860

Q37652953-CEA5F18C-89E4-427D-BFD5-7D5772249848 Q50054859-10D2CBF8-53D4-4DBA-9141-002597F4C004

P2860

Pooled analysis of the reports of carfilzomib, panobinostat, and elotuzumab combinations in patients with refractory/relapsed multiple myeloma.

Item

http://www.wikidata.org/entity/Q42425704

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Pooled analysis of the reports ...... ory/relapsed multiple myeloma.

@en

Pooled analysis of the reports ...... ory/relapsed multiple myeloma.

@nl

type

Item

label

Pooled analysis of the reports ...... ory/relapsed multiple myeloma.

@en

Pooled analysis of the reports ...... ory/relapsed multiple myeloma.

@nl

prefLabel

Pooled analysis of the reports ...... ory/relapsed multiple myeloma.

@en

Pooled analysis of the reports ...... ory/relapsed multiple myeloma.

@nl

P1476

Pooled analysis of the reports ...... ory/relapsed multiple myeloma.

@en

P2093

Lida Wang

http://www.w3.org/2001/XMLSchema#string

Liping Liu

http://www.w3.org/2001/XMLSchema#string

Ningning Zhao

http://www.w3.org/2001/XMLSchema#string

Wenjun Xu

http://www.w3.org/2001/XMLSchema#string

Zhixin Sheng

http://www.w3.org/2001/XMLSchema#string

P2860

Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.

Phase II study of melphalan, thalidomide and prednisone combined with oral panobinostat in patients with relapsed/refractory multiple myeloma.

Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma.

Phase Ib dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma.

PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma.

Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma.

Phase Ib study of panobinostat and bortezomib in relapsed or relapsed and refractory multiple myeloma.

A phase 1/2 study of oral panobinostat combined with melphalan for patients with relapsed or refractory multiple myeloma.

Replacement of bortezomib with carfilzomib for multiple myeloma patients progressing from bortezomib combination therapy.

Phase I study of 30-minute infusion of carfilzomib as single agent or in combination with low-dose dexamethasone in patients with relapsed and/or refractory multiple myeloma.

P2888

s13045-016-0286-x

P304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

meta-analysis

P356

10.1186/S13045-016-0286-X

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-07-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1028616333

http://www.w3.org/2001/XMLSchema#string

P698

27405295

http://www.w3.org/2001/XMLSchema#string

P932

4941034

http://www.w3.org/2001/XMLSchema#string

Pooled analysis of the reports of carfilzomib, panobinostat, and elotuzumab combinations in patients with refractory/relapsed multiple myeloma.

about

P2860

P2860

Pooled analysis of the reports of carfilzomib, panobinostat, and elotuzumab combinations in patients with refractory/relapsed multiple myeloma.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P6179

P698

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P6179

P698

P932